Hepatx GTM brain

HepaTx is developing an investigational stem-cell-based therapy for patients with late-stage liver disease as a potential alternative to transplantation.

category

Liver regenerative cell therapy

market profile

  • text: HepaTx is preclinical; its disclosed IND and first clinical trial dates are plans, not proof of approval or efficacy.
  • text: Mayo Clinic describes a research collaboration aimed at early clinical studies in alcohol-related hepatitis.

personas

  • title: Transplant hepatologist
    pains:
    • Patients with late-stage disease may not obtain a donor organ in time.
    • An investigational cell therapy needs strong safety and efficacy data before it can change treatment decisions.
  • title: Clinical research director at a liver center
    pains:
    • Needs a feasible trial pathway for severe liver disease and appropriate patients.
    • Must coordinate manufacturing quality, regulatory review and safety monitoring for cell-based trials.
  • title: Biopharma cell therapy partnership lead
    pains:
    • Must evaluate translational risk and scalable cell manufacturing before funding or partnering.
    • Needs clarity on indication, milestones and intellectual property.

icp

  • text: Academic liver and transplant centers capable of clinical research collaborations, initially illustrated by Mayo Clinic; specific account size is not disclosed.
  • text: Regenerative medicine investors and potential biopharma partners interested in preclinical liver cell therapies; partner fit is inferred.

message pillars

  • text: Pursue readily available cell treatments for liver disease.
  • text: Address the human cost of constrained liver care.
  • text: Pursue scalable manufacturing as a commercial goal; feasibility still requires proof.

objections

  • objection: Is it proven or approved as a transplant alternative?
    response: No such conclusion follows from the preclinical program; request current trial status and results as they become available.
  • objection: Can the cells be manufactured reliably and affordably?
    response: Request manufacturing and quality data and review it alongside clinical evidence; the company describes this as part of development.

competitors

  • name: Cellaion
    why: Develops cell-based tissue repair approaches for liver disease.
  • name: HepaRegeniX
    website: https://www.heparegenix.com/wp-content/uploads/20250508_HepaRegeniX_PR_EASL_FINAL.pdf
    why: Develops a small-molecule approach to liver regeneration in overlapping severe disease indications.
  • name: Resolution Therapeutics
    why: Develops macrophage cell therapy for advanced liver disease.

influencers

  • name: Eric Schuur
    why: Co-founder and CEO named in the company's fundraising material.

keywords

  • liver cell therapy
  • liver regeneration treatment
  • liver transplant alternatives
  • end stage liver disease clinical trials
  • stem cell therapy liver failure
  • alcohol associated hepatitis trials

voice

  • Mission-driven
  • Patient-focused
  • Optimistic about regenerative medicine

signals

  • text: A transplant center is recruiting studies for severe alcohol-related hepatitis or liver regeneration.
  • text: A biopharma team seeks a preclinical regenerative medicine collaboration in liver disease, an inferred signal.

pricing

model: unknown

motion

unknown

channels

  • scientific partnerships
  • investor crowdfunding

confidence

medium

Founders

  • name: Eric Schuur
    title: Founder/CEO
    role: CEO

Back to YC companies